The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.1 SPRAVATO® is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours,1 providing a new option for significant symptom relief until a longer-term, comprehensive treatment plan can take effect. Read more
Trumps calls on pharmaceutical execs to cut prices and move production back to U.S. and vows to work to streamline FDA approval process.
Johnson & Johnson is warning users of a cyber security bug in one of its insulin pumps that could allow a hacker to overdose diabetic patients, Reuters has learned. Fred Katayama reports.